Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
J Biol Chem ; 300(6): 107350, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38718865

RÉSUMÉ

The obligate intracellular bacterium, Chlamydia trachomatis, has evolved to depend on its human host for many metabolites, including most amino acids and three of the four nucleotides. Given this, it is not surprising that depletion of a single amino acid in the host cell growth medium blocks chlamydial replication. Paradoxically, supra-normal levels of some amino acids also block productive replication of Chlamydia. Here, we have determined how elevated serine levels, generated by exogenous supplementation, impede chlamydial inclusion development and reduce the generation of infectious progeny. Our findings reveal that human serine racemase, which is broadly expressed in multiple tissues, potentiates the anti-chlamydial effect of elevated serine concentrations. In addition to reversibly converting l-serine to d-serine, serine racemase also deaminates serine via ß-elimination. We have determined that d-serine does not directly impact Chlamydia; rather, ammonia generated by serine deamination limits the productive chlamydial replication. Our findings imply that ammonia produced within host cells can traverse the chlamydial inclusion membrane. Further, this property of serine deaminase can be exploited to sensitize Chlamydia to concentrations of doxycycline that are otherwise not bactericidal. Because exogenously elevated levels of serine can be tolerated over extended periods, the broad expression pattern of serine racemase indicates it to be a host enzyme whose activity can be directed against multiple intracellular bacterial pathogens. From a therapeutic perspective, demonstrating host metabolism can be skewed to generate an anti-bacterial metabolite that synergizes with antibiotics, we believe our results provide a new approach to target intracellular pathogens.


Sujet(s)
Antibactériens , Chlamydia trachomatis , Sérine , Humains , Chlamydia trachomatis/métabolisme , Chlamydia trachomatis/effets des médicaments et des substances chimiques , Sérine/métabolisme , Antibactériens/pharmacologie , Cellules HeLa , Racémases et épimérases/métabolisme , Désamination , Infections à Chlamydia/métabolisme , Infections à Chlamydia/traitement médicamenteux , Infections à Chlamydia/microbiologie
2.
Article de Anglais | MEDLINE | ID: mdl-24959423

RÉSUMÉ

In vitro models of Chlamydia trachomatis growth have long been studied to predict growth in vivo. Alternative or persistent growth modes in vitro have been shown to occur under the influence of numerous stressors but have not been studied in vivo. Here, we report the development of methods for sampling human infections from the endocervix in a manner that permits a multifaceted analysis of the bacteria, host and the endocervical environment. Our approach permits evaluating total bacterial load, transcriptional patterns, morphology by immunofluorescence and electron microscopy, and levels of cytokines and nutrients in the infection microenvironment. By applying this approach to two pilot patients with disparate infections, we have determined that their contrasting growth patterns correlate with strikingly distinct transcriptional biomarkers, and are associated with differences in local levels of IFNγ. Our multifaceted approach will be useful to dissect infections in the human host and be useful in identifying patients at risk for chronic disease. Importantly, the molecular and morphological analyses described here indicate that persistent growth forms can be isolated from the human endocervix when the infection microenvironment resembles the in vitro model of IFNγ-induced persistence.


Sujet(s)
Col de l'utérus/microbiologie , Infections à Chlamydia/microbiologie , Chlamydia trachomatis/cytologie , Chlamydia trachomatis/génétique , Infections de l'appareil reproducteur/microbiologie , Adolescent , Adulte , Charge bactérienne , Chlamydia trachomatis/isolement et purification , Cytokines/analyse , Femelle , Technique d'immunofluorescence , Analyse de profil d'expression de gènes , Humains , Techniques microbiologiques/méthodes , Microscopie électronique , Anatomopathologie/méthodes , Jeune adulte
3.
Infect Immun ; 79(11): 4425-37, 2011 Nov.
Article de Anglais | MEDLINE | ID: mdl-21911470

RÉSUMÉ

Gamma interferon (IFN-γ) induces expression of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) in human epithelial cells, the permissive cells for the obligate intracellular bacterium Chlamydia trachomatis. IDO1 depletes tryptophan by catabolizing it to kynurenine with consequences for C. trachomatis, which is a tryptophan auxotroph. In vitro studies reveal that tryptophan depletion can result in the formation of persistent (viable but noncultivable) chlamydial forms. Here, we tested the effects of the IDO1 inhibitor, levo-1-methyl-tryptophan (L-1MT), on IFN-γ-induced C. trachomatis persistence. We found that addition of 0.2 mM L-1MT to IFN-γ-exposed infected HeLa cell cultures restricted IDO1 activity at the mid-stage (20 h postinfection [hpi]) of the chlamydial developmental cycle. This delayed tryptophan depletion until the late stage (38 hpi) of the cycle. Parallel morphological and gene expression studies indicated a consequence of the delay was a block in the induction of C. trachomatis persistence by IFN-γ. Furthermore, L-1MT addition allowed C. trachomatis to undergo secondary differentiation, albeit with limited productive multiplication of the bacterium. IFN-γ-induced persistent infections in epithelial cells have been previously reported to be more resistant to doxycycline than normal productive infections in vitro. Pertinent to this observation, we found that L-1MT significantly improved the efficacy of doxycycline in clearing persistent C. trachomatis forms. It has been postulated that persistent forms of C. trachomatis may contribute to chronic chlamydial disease. Our findings suggest that IDO1 inhibitors such as L-1MT might provide a novel means to investigate, and potentially target, persistent chlamydial forms, particularly in conjunction with conventional therapeutics.


Sujet(s)
Chlamydia trachomatis/effets des médicaments et des substances chimiques , Cellules épithéliales/microbiologie , Indoleamine-pyrrole 2,3,-dioxygenase/antagonistes et inhibiteurs , Interféron gamma/pharmacologie , Tryptophane/analogues et dérivés , Antibactériens/pharmacologie , Chlamydia trachomatis/physiologie , Relation dose-effet des médicaments , Doxycycline/pharmacologie , Cellules HeLa , Humains , Indoleamine-pyrrole 2,3,-dioxygenase/métabolisme , Cynurénine/analyse , Facteurs temps , Tryptophane/analyse , Tryptophane/pharmacologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE